Trade this ETF at your broker
Index | ROBO Global Healthcare Technology and Innovation |
Investment focus | Equity, World, Health Care |
Fund size | EUR 64 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 18.25% |
Inception/ Listing Date | 2 July 2019 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | No ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
Moderna, Inc. | 2.81% |
Guardant Health, Inc. | 2.45% |
Koninklijke Philips NV | 2.28% |
Natera | 2.26% |
STAAR Surgical | 2.15% |
NovoCure | 2.11% |
Omnicell | 2.02% |
Boston Scientific Corp. | 2.00% |
DiaSorin SpA | 1.99% |
Artivion | 1.93% |
United States | 78.50% |
Switzerland | 5.46% |
Netherlands | 2.28% |
Jersey | 2.11% |
Other | 11.65% |
Health Care | 93.81% |
Consumer Discretionary | 1.27% |
Technology | 1.24% |
Basic Materials | 0.56% |
Other | 3.12% |
Broker | Rating | Execution fee | Account fee | More information |
---|---|---|---|---|
![]() | free of charge | free of charge | View offer* | |
![]() | free of charge | free of charge | View offer* | |
![]() | free of charge | free of charge | View offer* | |
![]() | free of charge | free of charge | View offer* | |
![]() | EUR 1.50 1.50% | free of charge | View offer* |
YTD | +2.86% |
1 month | +0.19% |
3 months | +3.06% |
6 months | +2.57% |
1 year | -5.85% |
3 years | -34.29% |
5 years | +21.78% |
Since inception (MAX) | +23.74% |
2023 | -6.26% |
2022 | -29.18% |
2021 | +8.52% |
2020 | +51.67% |
Volatility 1 year | 18.25% |
Volatility 3 years | 24.57% |
Volatility 5 years | 25.52% |
Return per risk 1 year | -0.32 |
Return per risk 3 years | -0.53 |
Return per risk 5 years | 0.16 |
Maximum drawdown 1 year | -25.59% |
Maximum drawdown 3 years | -50.52% |
Maximum drawdown 5 years | -50.89% |
Maximum drawdown since inception | -50.89% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | XMLH | - - | - - | - |
Borsa Italiana | EUR | DOCT | DOCT IM DOCEURIV | DOCT.MI DOCTEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | DOCG | DOCG LN NA | DOCG.L NA | Flow Traders B.V. |
London Stock Exchange | USD | DOCT | DOCT LN NA | DOCT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | DOCT | DOCT SW DOCEURIV | DOCT.S | Flow Traders B.V. |
XETRA | EUR | XMLH | XMLH GY DOCEURIV | DOCT.DE | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,022 | 0.40% p.a. | Accumulating | Sampling |
L&G Pharma Breakthrough UCITS ETF | 17 | 0.49% p.a. | Accumulating | Full replication |
HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF | 15 | 0.59% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 7 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |